Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience

PURPOSE: Docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) regimen is frequently used to treat early and locally advanced human epidermal growth factor receptor 2 (HER2)–positive breast cancer (BC) in neoadjuvant setting. However, large-scaled real-world evidence did not exist. MATERIALS AND METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ji-Yeon, Nam, Seok Jin, Lee, Jeong Eon, Yu, Jonghan, Chae, Byung Joo, Lee, Se Kyung, Ryu, Jai Min, Ahn, Jin Seok, Im, Young-Hyuck, Kim, Seok Won, Park, Yeon Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582484/
https://www.ncbi.nlm.nih.gov/pubmed/35008143
http://dx.doi.org/10.4143/crt.2021.901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582484/
https://www.ncbi.nlm.nih.gov/pubmed/35008143
http://dx.doi.org/10.4143/crt.2021.901

Ejemplares similares